Exosomes in Dermatology: A Research Overview for Clinicians

Dermatology sits at an interesting intersection for regenerative medicine research. The skin is the body's largest organ, directly accessible to practitioners, and capable of measurable changes over clinically relevant timeframes. These properties make it an active site of investigation for emerging biologics including MSC-derived exosomes. Over the past several years, a growing body of preclinical and early-stage clinical literature has explored how exosomes interact with skin cells, wound microenvironments, and inflammatory signaling pathways.1

This article provides a research-oriented overview for licensed practitioners who are encountering exosome-based products in the marketplace and want a grounded understanding of the underlying science, regulatory landscape, and supplier evaluation criteria. It is not a clinical protocol guide, and nothing here constitutes an endorsement of exosome use for any specific dermatological indication.

Skin Biology: A Foundation for Understanding Exosome Research

Skin is a multilayered organ composed of the epidermis, dermis, and hypodermis, each with distinct cellular populations and structural functions (Fig. 1). The epidermis is maintained by keratinocytes that continuously migrate from the basal layer toward the surface. The dermis provides structural support through a dense extracellular matrix (ECM) of collagen and elastin fibers, maintained by fibroblasts. Beneath both layers, the hypodermis consists largely of adipose tissue.

Cell-to-cell communication is fundamental to skin homeostasis and repair. When skin is injured, a coordinated cascade of signaling events recruits inflammatory cells, activates keratinocytes to close the wound, stimulates fibroblasts to deposit new collagen (Fig. 2), and drives angiogenesis to restore vascular supply. Disruptions in any of these signaling steps can lead to impaired healing, excessive scarring, or chronic wound states. Exosome research in dermatology centers on the question of whether exosome-mediated signaling can modulate these processes in ways relevant to clinical practice.

Mechanisms Under Investigation

MSC-derived exosomes carry a complex cargo of proteins, lipids, mRNAs, and microRNAs that vary by source tissue and manufacturing protocol. Research across in vitro and preclinical in vivo models has identified several signaling interactions of potential relevance to dermatology (Fig. 3).2

A critical reading of this literature requires attention to the gap between preclinical findings and clinical outcomes. Cell culture and animal model results do not reliably predict human clinical responses, and dermatology exosome research has not yet produced the volume of large, controlled human trials needed to establish clinical efficacy for specific indications. This is a rapidly developing field, and practitioners should approach it accordingly.4

Wound Healing Research: Where the Evidence is Strongest

Among dermatological application areas, wound healing has the largest body of exosome research. MSC-derived extracellular vesicles have been studied in diabetic wound models, burn wound models, and excisional wound models across multiple preclinical species. Consistent findings in these models include accelerated wound closure rates, reduced inflammatory infiltrate, and altered collagen deposition patterns relative to control conditions.4

Human clinical data in wound healing is more limited. A small number of case reports and pilot studies describe exosome application in chronic or difficult-to-heal wounds, but these are not controlled trials and cannot establish causality. Readers of this literature can separate the preclinical signal in wound models, which is relatively consistent, from the human evidence base, which remains early-stage, and the wound models appear in this article as research subjects only.

Post-Procedure Applications: Practitioner Reports and Research Framing

One of the most common clinical contexts in which practitioners report using exosomes is following ablative or semi-ablative skin procedures such as fractional CO2 laser, radiofrequency microneedling, and chemical peels. The rationale typically draws from wound healing research: post-procedure skin exhibits transient inflammation, barrier disruption, and active tissue remodeling that may create a permissive environment for exosome-mediated signaling.

Delivery in these settings is most commonly topical application following microchannel creation, which is thought to improve penetration beyond the intact stratum corneum. Some practitioners also report intradermal or subdermal injection of exosome preparations; ExaVeyra supplies exosome material for topical aesthetic use only. Neither approach has been validated in large controlled trials for post-procedure applications specifically.

What practitioners should understand is that the wound healing research supporting exosome interest in this space was largely conducted in chronic or acute wound models, not in the post-procedure context specifically. The biological rationale for extrapolation exists, but it should not be treated as established evidence for post-procedure efficacy.

Source Tissue and Characterization: What Matters for Dermatology

MSC-derived exosomes used in dermatology research come primarily from three source tissues: adipose-derived MSCs (AD-MSCs), umbilical cord MSCs (UC-MSCs), and bone marrow MSCs (BM-MSCs). Each source produces a distinct exosome population with differences in cargo composition, surface markers, and yield per cell. These differences are biologically meaningful and may influence how exosomes interact with specific cell types in the skin.1

For clinicians evaluating products, source tissue should be disclosed by the supplier with supporting characterization data. A Certificate of Analysis (COA) should confirm particle identity through established surface marker testing (CD9, CD63, CD81), and particle concentration should be determined by nanoparticle tracking analysis (NTA). These are baseline quality documentation expectations, not advanced requirements.

Exosomes vs PRP in Dermatology: Key Differences for Practitioners

Some practitioners combine exosome topical application with PRP injection in post-procedure protocols, citing the complementary delivery routes and biological rationale. Published data specifically on combined protocols is sparse. Practitioners should approach combination use with appropriate documentation and informed consent practices.

Regulatory Status: What Practitioners Need to Know

The FDA public safety notification of 6 December 2019 states that there are currently no FDA-approved exosome products, and that exosome products used to treat diseases and conditions in humans are regulated as drugs and biological products under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act, subject to premarket review and approval. Exosome material distributed by ExaVeyra Sciences is supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and it is not intended to diagnose, treat, cure or prevent any disease.

The 2019 notification addresses exosome products intended to treat diseases or conditions, which require premarket review, and it does not speak to topical aesthetic labeling. ExaVeyra supplies material that its manufacturer labels for topical aesthetic use, to licensed practitioners, as its own supply position rather than an FDA determination, and whether a given use stays within that labeling is a determination for the practice and its counsel. Matching the material, its labeling and the procedure is the foundation of a well-documented program.

Due diligence before purchasing any exosome product includes verifying the manufacturer's regulatory status, reviewing all available clinical evidence independently, confirming COA documentation, and consulting with qualified legal and regulatory counsel. Practitioners also have an obligation to obtain informed consent that accurately describes the material, its labeled topical aesthetic use and the current state of the evidence.

Supplier Due Diligence: Five Starting Points

Frequently Asked Questions